Search research articles
Contact Us
Filters
Showing results (121-130 of 129) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 129 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer
G Bolis, G Favalli, S Danese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
C Lavarino, S Pilotti, M Oggionni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1996
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study
G J Creemers, G Bolis, M Gore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1997
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
W ten Bokkel Huinink, M Gore, J Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2001
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer
M Gore, W ten Bokkel Huinink, J Carmichael, et al.
Gynecologic Oncology
|
May 24, 2001
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer
H C Wagenaar, N Colombo, I Vergote, et al.
European Journal of Gynaecological Oncology
|
August 15, 2001
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer
H C Wagenaar, S Pecorelli, I Vergote, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
F H van Wijk, M S Aapro, G Bolis, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 129) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 129 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer
G Bolis, G Favalli, S Danese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
C Lavarino, S Pilotti, M Oggionni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1996
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study
G J Creemers, G Bolis, M Gore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1997
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
W ten Bokkel Huinink, M Gore, J Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2001
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer
M Gore, W ten Bokkel Huinink, J Carmichael, et al.
Gynecologic Oncology
|
May 24, 2001
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer
H C Wagenaar, N Colombo, I Vergote, et al.
European Journal of Gynaecological Oncology
|
August 15, 2001
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer
H C Wagenaar, S Pecorelli, I Vergote, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
F H van Wijk, M S Aapro, G Bolis, et al.
Page
of 13